Recent studies have converged on the convergence of GLP|GIP|GCGR stimulant therapies and DA signaling. While GLP agonists are widely employed for managing type 2 diabetes, their potential consequences on reward https://tirzepatide834540.timeblog.net/77711901/emerging-glp-stimulators-and-da-adjustment-a-comparative-examination